Sensus Healthcare Award

download Sensus Healthcare Award

of 13

  • date post

    16-Feb-2017
  • Category

    Healthcare

  • view

    91
  • download

    0

Embed Size (px)

Transcript of Sensus Healthcare Award

  • 2016 GlobalNon-Melanoma Skin Cancer Therapy

    Technology Leadership Award

    2016

  • BEST PRACTICES RESEARCH

    Frost & Sullivan 2016 2 We Accelerate Growth

    Contents Background and Company Performance ........................................................................ 3

    Industry Challenges .............................................................................................. 3

    Technology Leverage and Business Impact .............................................................. 4

    Conclusion........................................................................................................... 6

    Significance of Technology Leadership .......................................................................... 7

    Understanding Technology Leadership .......................................................................... 7

    Key Benchmarking Criteria .................................................................................... 8

    Best Practice Award Analysis for Sensus Healthcare ........................................................ 8

    Decision Support Scorecard ................................................................................... 8

    Technology Leverage ............................................................................................ 9

    Business Impact ................................................................................................... 9

    Decision Support Matrix ...................................................................................... 10

    The Intersection between 360-Degree Research and Best Practices Awards ..................... 11

    Research Methodology ........................................................................................ 11

    Best Practices Recognition: 10 Steps to Researching, Identifying, and Recognizing Best Practices ................................................................................................................. 12

    About Frost & Sullivan .............................................................................................. 13

  • BEST PRACTICES RESEARCH

    Frost & Sullivan 2016 3 We Accelerate Growth

    Background and Company Performance Industry Challenges

    Skin cancer is the most commonly diagnosed type of cancer in the United States. According to the World Health Organization, one in three diagnosed cancers is a form of skin cancer. The American Cancer Society (ACA) estimates that every year, nearly 5.5 million Americans are diagnosed with skin cancer - over 5 million of whom have non-melanoma skin cancer (NMSC). NMSCs are tumors that originate either in the basal cells (basal-cell carcinoma, BCC) or squamous cells (squamous-cell carcinoma, SCC) of the skin. While NMSCs are malignant and can potentially metastasize to other cells, they are distinct from the far deadlier melanoma skin cancer. Nearly 80% of all skin cancers are BCC, making it the most common type of skin cancer. The silver lining to these grim statistics is that NMSCs have a much better survival rate than other cancers. If detected early, NMSCs present a survival rate of 90% or more. In fact, this type of cancer is eminently treatable, and the number of deaths associated with NMSC is less than 1% of all cancer deaths. Frost & Sullivan consistently tracks several well-established surgical and non-surgical approaches that are available for the treatment of NMSCs. Mohs surgery is widely regarded to be the gold standard for skin cancer therapy. This is a microscopically-controlled procedure that relies on real-time visual examination of tissue during the surgery for informed tissue excision. Mohs surgery is preferred for its ability to operate with very narrow surgical margins (minimal loss of healthy tissue loss) and its high cure rate. Various clinical studies concur that the cure rate of Mohs surgery is above 97%. As such, Frost & Sullivan notes that there is very little doubt about the procedures clinical efficacy. Where the procedure stands exposed is in relation to the cost and effort involved. The procedure requires highly skilled technicians working on tissue handling, imaging, and surgery. Hospitals in rural areas and in developing countries of Southeast Asia and Africa, all of which house considerable NMSC populations, may find a shortage of skilled professionals for surgeries. The cost of the procedure (which can run into tens of thousands of dollars) and its duration are both considerable factors, given how commonplace the cancer is. However, what truly ails this approach is the considerable patient discomfort associated with it. Mohs surgery leaves the patient with visible scars, and many patients opt for cosmetic reconstructive surgeries, especially if the scars are on the face. For the rest, the scars are a constant reminder of the trauma of cancer. Frost & Sullivan points out that the recovery time needed after the procedure and the vulnerability of the patients to post-surgical infections also add to the list of limitations of Mohs surgery.

  • BEST PRACTICES RESEARCH

    Frost & Sullivan 2016 4 We Accelerate Growth

    Advances in diagnoses, increasing awareness, and the nature of the disease itself have made the management of NMSC ripe for overhaul. Frost & Sullivan agrees that this creates an urgent market need for a patient-friendly, clinically-effective, and aesthetically-appealing option for the treatment of NMSC. Technology Leverage and Business Impact

    Commitment to Creativity The natural alternative to surgical treatment of NMSC is radiation therapy - particularly external beam radiotherapy. High-energy X-rays (6 to 12 mega electron-volt, or MeV) are employed to kill malignant cells. While certainly effective in killing cancerous cells, these devices subject patients to ionizing radiation that is several orders of magnitude stronger than those required to treat NMSC. Understanding this crucial unmet need, Sensus Healthcare (Boca Raton, Florida) has developed a portfolio of products that use low-energy X-rays for the treatment and management of NMSC. Sensus products SRT-100 and SRT-100 Vision leverage a technique known as superficial radiation therapy (SRT) that delivers X-rays with the optimum energy needed (10 to 100 kilo electron-volts, or KeV) to penetrate the skin to the depth where malignant squamous and basal cells are located (2.5 to 5 millimeters below the skins surface). Frost & Sullivan recognizes how SRT bests the competition from radiation therapy and surgery by providing a scar-free, aesthetically-appealing, and clinically-effective therapy. Commitment to Innovation SRT-100, Sensus first-generation product was the first cart-based portable radiotherapy system. Since its launch in 2010, SRT-100 has been used to treat over 200,000 NMSC cases. The compact size of the system and its portability make it suitable for use in clinics and smaller hospitals. Instead of referring patients to a separate radiation oncology center or facility, dermatologists can treat patients in their own clinics. Sensus latest product, SRT-100 Vision, is a first-of-its-kind product that offers high-frequency ultrasound guidance to radiation treatment. The ultrasound capability helps dermatologists view lesions, accurately map the boundaries of the tumor, quantify tumor volume, and determine the optimum energy required for the procedure. SRT-100 Vision eliminates any lingering doubts regarding over-dosage and helps accurately map the area that has to be irradiated. In effect, the ultrasound capability equips the SRT procedure with the kind of visual confirmation that helps Mohs surgery keep treatment margins to a minimum.

  • BEST PRACTICES RESEARCH

    Frost & Sullivan 2016 5 We Accelerate Growth

    Application Diversity Although SRT is the foremost alternative to NMSC surgery, its true potential lies in the diversity of its application. The SRT platform has been designed and approved to treat and manage several non-oncology skin conditions - such as keloids, actinic keratosis (AK), and warts. Apart from NMSC, keloids are the most significant market for SRT-100 and SRT-100 Vision. Keloids are collagen-based scars that remain behind after events like surgeries and accidents. While keloids do not present any health hazard, their presence is chronic unless treated. Cosmetic surgery is only partially effective, as evidenced by their reappearance in over 90% of the cases. As an adjunct treatment option, SRT has proven to be quite effective and has reduced recurrence to as low as 10%. AK is a skin condition that is commonly associated with UV exposure and manifests as crusty patches on the skin. AK is usually considered to be a pre-cancerous condition. In other words, if left untreated, it can develop into squamous cell carcinoma (SCC). In fact, The Skin Cancer Foundation estimates that over 10% of the 58 million cases of AC in the US can develop into SCC, underscoring the importance of early and effective treatment. Customer Acquisition Sensus Healthcare is clear in their outlook for SRT; despite its numerous patient benefits, it is not intended to replace Mohs surgery as the first-in-line treatment option for NMSC. However, there are several conditions under which SRT may be the optimal choice for patients. For instance, diabetics, cardiac patients, and those considered high-risk for surgery are ideal candidates for SRT. Similarly, for those particular about the cosmetic outcome of therapy (especially if tumors or keloids appear on the nose or the ear, as they tend to do), would find SRT preferable to surgery. SRT offers patients freedom from hospitalization and post-surgical recovery; it also offers physicians and hosp